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ABSTRACT 
Background: D-004, a lipid extract of the fruit of Roystonea regia, contains a 
mixture of fatty acids--mainly oleic, lauric, palmitic, and myristic acids, with 
oleic acid being among the most abundant--that has been found to reduce the 
risk for prostatic hyperplasia (PH) induced with testosterone (T) in rats. The 
pharmacokinetic profile of D-004 has not been reported. 
Objective: The objective of this study in rats was to assess plasma levels, 
tissue distribution, and excretion of total radioactivity (TR) after single-dose 
administration of oral D-004 radiolabeled with (3H)-oleic acid, as a surrogate for 
the pharmacokinetics of D-004. 
Methods: This experimental study was conducted at the Pharmacology 
Department, Center of Natural Products, National Center for Scientific Research, 
Havana, Cuba. Single doses of suspensions of (3H)-oleic acid 0.16 pCi/mg mixed 
with D-004 400 mg/kg (radioactive dose/animal 7.2 pCi) were given orally to 
male Wistar rats weighing 150 to 200 g assigned to the treated or control group. 
Three rats were euthanized at each of the following times: 0.25, 0.5, 1, 1.5, 2, 4, 
8, 24, 48, 72, 96, and 144 hours after study drug administration. After adminis- 
tration, the rats euthanized at the last experimental time point were housed 
individually in metabolism cages. Urine and feces samples were collected aily. 
At each time point, blood samples were drawn and plasma samples were 
obtained using centrifugation. After euthanization, tissue samples (liver, lungs, 
spleen, brain, kidneys, adipose tissue, muscle, stomach, small and large intes- 
tines, adrenal glands, heart, testes, prostate, and seminal vesicles) were quickly 
removed, washed, blotted, and homogenized. Plasma (100 IJL), tissue aliquots 
(100 mg), feces (10 mg), and urine (100 IJL) were dissolved and TR was measured. 
Samples were assayed in duplicate. Results were expressed in l.lgEq of radiola- 
beled oleic acid per milliliter of plasma or urine or gram of tissue or feces. Plasma, 
tissue, feces, and urine samples of rats that did not receive (3H)-oleic acid were 
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used as controls. Excretion was expressed as the percentage of the radioactivi- 
ty excreted via each route with respect o the total radioactive dose adminis- 
tered to each rat. 
Results: A total of 50 rats were included in the experiment (mean age, 4 weeks; 
mean weight, 310 g). Absorption was rapid; mean Cma xwas 195.56 (31.12) pgEq/mL, 
and mean Tma x was 2 hours. Thereafter, a biphasic decay of TR was found: a 
rapid first phase (tl/2W 1.33 hours), followed by a slower second elimination 
phase (tl/213, 36.07 hours). Radioactivity was rapidly and broadly distributed 
throughout the tissues, with more accumulating in the prostate than elsewhere. 
In the first 8 hours, accumulation of TR was greatest in the prostate, followed 
by the liver, small intestine, and plasma. Subsequently, TR increased in the 
small intestine, while it decreased in the liver and plasma. In contrast, over the 
periods of 24 and 144 hours after administration, TR increased in the adipose 
tissue, while it decreased in the other tissues and plasma. During those inter- 
vals, TR was greatest in the prostate, followed by adipose tissue. Mean peak 
radioactivity in the prostate (562.41 pgEq/g) was reached at 4 hours and 
decreased slowly thereafter. The prostate had the highest values of tl/2~ and 
cumulative AUC compared with the other tissues and plasma. Mean (SD) TR 
was similar in feces (33.48% [4.90%]) and urine (28.96% [5.32%]), with total 
excretion being 62.40% (5.90%) of the administered ose. 
Conclusions: In this experimental study, after single-dose administration of 
oral D-004 radiolabeled with (3H)-oleic acid in rats, TR was rapidly and widely 
distributed across the tissues, with the prostate having the highest accumula- 
tion of radioactivity. Excretion of TR was limited, with similar amounts being 
excreted in feces and urine. The broad distribution of radiolabeled oleic acid 
and/or its metabolites suggests a pharmacokinetic rationale for the effectiveness 
of D-004 in reducing the risk for PH induced with T in rats. (Curr Ther Res Clin 
Exp. 2006;67:406--419) Copyright © 2006 Excerpta Medica, Inc. 
Key words: oleic acid pharmacokinetics, D-004, Roystonea regia lipid extract, 
royal palm lipid extract. 
INTRODUCTION 
Benign prostatic hyperplasia (BPH), the uncontrolled, benign growth of the 
prostate that often results in difficulty urinating, is observed frequently in men 
aged ___50 years3 -5 Drug therapy, mainly with prostate 50¢-reductase inhibitors 
and %-adrenoreceptor blockers, is the most common treatment of BPH. 1-7 
Herbal medicines are also commonly used to treat BPH. In most cases, the effec- 
tiveness of herbal products is due to multiple mechanisms because they con- 
tain a mixture of compounds. 8 
The lipidosterolic extract (LE) of saw palmetto berries (Serenoa repens), a 
palm of the Arecaceae family, is the main alternative treatment for BPH, having 
fewer associated adverse ffects compared with conventional drugs. 9-16 The LE 
of saw palmetto consists of _>80% free fatty acids (eg, lauric acid [16%-38%], 
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oleic acid [9%-24%], capric acid [0.8%-3.2%], caprylic acid [0.9%-2.7%], myris- 
tic acid [6.5%-15%], palmitic acid [4%-8.8%], stearic acid [0.4%-1.2%], linoleic 
acid [0.7%-3.4%], and linolenic acid [0.2%-0.7%]), while other compounds are 
present in lesser proportions. 9,1°,12,13 
Despite the extensive use of saw palmetto LE, published pharmacokinetic 
studies are scarce, based on a MEDLINE search (key terms: Serenoa repens, phar- 
macokinetics, and distribution; years: 1990-2006). 9,1°,17,18 A study conducted in 
rats treated orally with saw palmetto LE radiolabeled with (14C)-oleic and 
-lauric acids has found that the prostate contained the highest concentration of
radioactivity compared with other organs, 16 supporting ood bioavailability of 
the medication in the target organ. 
D-004, a lipid extract of the fruit of the Cuban royal palm (Roystonea regia), 
also contains a reproducible mixture of fatty acids, with oleic acid being the 
most abundant, followed by lauric, palmitic, and myristic acids. In rodents, oral 
treatment with D-004 was found to reduce the incidence of prostatic hyperpla- 
sia (PH) induced with testosterone (T) but not with dihydrotestosterone, sug- 
gesting that it may act by inhibiting prostate 50¢-reductase activity. 19-22 The 
pharmacokinetic profile of D-004 has not been reported. 
Oleic acid, the most abundant component of D-004, has been found to inhibit 
prostate 50¢-reductase activity in rats. 23 Therefore, the pharmacokinetic proper- 
ties of oleic acid can be used as a surrogate for the pharmacokinetic properties 
of the components of D-004. The present study explored plasma levels, tissue 
distribution, and excretion of radioactivity after single-dose administration of 
oral D-004 radiolabeled with (3H)-oleic acid in rats. 
MATERIALS AND METHODS 
This experimental study was conducted at the Pharmacology Department, Center 
of Natural Products, National Center for Scientific Research, Havana, Cuba. 
Animals 
Male Wistar rats weighing 150 to 200 g were obtained from the National 
Center for Laboratory Animal Production (CENPALAB, Havana, Cuba) and 
adapted for 14 days to laboratory conditions (temperature 25°C + 2°C, humid- 
ity 60% _+ 5%, and 12-hour dark-light cycles). Free access to food (rodent chow 
purchased at CENPALAB) and tap water was allowed. 
The study protocol was reviewed and approved by both an independent 
institutional review board and the Quality Assurance Unit of the Center of 
Natural Products (Havana, Cuba), and animals were handled according to the 
Cuban Ethical Code for Care of Laboratory Animals. 
Study Drug Administration 
(3H)-oleic acid 0.16 pCi/mg (Amershan GmbH, Stockholm, Sweden) was used as 
the labeled substrate. Fresh suspensions in Tween 36/water (2%) vehicle (Merck 
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GmbH, Berlin, Germany) were prepared by mixing (3H)-oleic acid with 
D-004 2 hours before dosing. Rats were treated with D-004 400 mg/kg (radioactive 
dose/rat 7.2 iJCi). Since D-004 administered orally in rats has been found to be 
effective in reducing the risk for PH induced with T in vivo, 19-22 we determined 
that this dose should reach the prostate, the target organ for such an effect. 
Because we were using the pharmacokinetic data for oleic acid as a surrogate 
for the pharmacokinetic properties of the components of D-004, we mixed oleic 
acid with D-004 instead of administering the radiolabeled substrate alone. 
Treatments were administered orally using gastric gavage (1 mL/200 g) at 8:30 AM. 
In addition, groups of rats treated with vehicle alone or similar doses of D-004, but 
not with the radioactive compound (controls), were included to assess whether 
radioactive cross-contamination was present and to calculate the total radioac- 
tivity (TR) for each sample, subtracting any background radioactivity. 
Measurement of Radioactivity in Plasma and Tissues 
After study drug administration, 3 rats were anesthetized with ether and 
exsanguinated through the abdominal aorta at 0.25, 0.5, 1, 1.5, 2, 4, 8, 24, 8, 72, 
96, and 144 hours after study drug administration. Blood samples were drawn 
into heparinized tubes, and plasma was obtained by centrifugation at 3000 rpm 
at 25°C for 20 minutes. 
The tissues (liver, lungs, spleen, brain, kidneys, adipose tissue [dorsal subcu- 
taneous], muscle [right leg], stomach, and small and large intestines [the most 
proximal and distal position, respectively], adrenal glands, and heart, testes, 
prostate, and seminal vesicles) were quickly removed, washed in cold (10°C) 
0.9% sodium chloride, blotted with filter paper, and weighed and homogenized 
into the counting vials. Aliquots of plasma (100 IJL) and tissues (100 mg) were 
dissolved into the counting vials by adding 200 and 500 IJL of Tissue Solubilizer 
(TS) (BDH Laboratory Supplies, Poole, England), respectively, and were main- 
tained at 40°C for 20 minutes. When required, samples were blanched with 
hydrogen peroxide (1-[202) (30 Wt~o sol in water) and acidified with acetic acid. 
Measurement of Radioactivity in Urine and Feces 
After study drug administration, rats euthanized at the last experimental 
time point were housed individually in metabolism cages. Urine (100 IJL) and 
feces (10 mg) were collected daily. To ensure uniform volumes, urine samples 
were diluted with distilled water and later shaken and treated as described pre- 
viously for plasma samples to determine TR. Feces were dried at 60°C overnight 
and weighed. Once powdered and homogenized with a mortar, 10-mg samples 
were transferred into scintillation vials and hydrated with distilled water 
(200 IJL) and TS (1 mL). The mixture was stirred at 60°C until it was totally dis- 
solved. Samples were blanched with H202 30%, acidified with acetic acid (30 IJL), 
and allowed to stand for at least 30 hours before radioactivity was measured. 
For TR measurements, scintillation liquid (10 mL) was added to all prepared 
samples. Radioactivity was measured as TR; whether it corresponded to un- 
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changed (3H)-oleic acid and/or metabolites was not determined. All samples 
were assayed in duplicate for radioactivity in a RACKBETA model 1219 liquid 
scintillation spectrometer (Pharmacia LKB Biotechnology, Uppsala, Sweden), 
and radioactivity was determined by adding 15 mL of Cocktail T (BDH Labora- 
tory Supplies). Counting efficiencies were determined automatically using the 
equipment, and quenching corrections were performed using the external stan- 
dard method. 
TR data (dpm/min) were expressed as pgEq of the radiolabeled oleic acid per 
milliliter of plasma or urine or per gram of tissue or feces. For this calculation, 
the specific activity of (3H)-oleic acid mixed in D-004 was estimated. Because of 
the high specific activity of the radiolabeled compound (10.0 Ci/mmol) added 
to the isotopic mixture diluted in D-004, we assumed the mass contribution of 
radiolabeled oleic acid to the overall mass of oleic acid present in the mixture 
to be negligible. The final TR value of each sample was calculated after subtract- 
ing the radioactivity determined in similar samples of rats that were not admin- 
istered the radiolabeled compound. 
Pharmacokinetic Analysis 
Pharmacokinetic properties were calculated using WinNonlin version 2.1 
(Pharsight Corporation, Mountain View, California) based on a 2-compartment 
and a noncompartmental model for calculating the AUC of the plasma profile 
and the tissue distribution, respectively. Excretion was expressed as the per- 
centage of the radioactivity excreted via each route with respect o the total 
radioactive dose administered to each rat. 
RESULTS 
A total of 50 rats were included in the experiment (mean age, 4 weeks). 
Plasma Profile of Total Radioactivity and Absorption 
Figure 1 shows the plasma TR-versus-time profile after oral dosing of D-004 
radiolabeled with (3H)-oleic acid, and Table I shows the experimental nd pre- 
dicted values of the pharmacokinetic parameters measured. 
Mean (SD) experimental Cma ~ was 195.56 (31.12) pgEq/mL, and mean Tma x 
was 2 hours, with a biphasic decrease observed thereafter. Thus, an open, 
2-compartment pharmacokinetic model fit this plasma concentration-time pattern 
well (r 2 = 0.99); the first distribution phase was rapid (tl/2~, 1.33 hours) and was 
followed by a slower second elimination phase (tl/2~, 36.07 hours). The xperi- 
mental (195.56 pgEq/mL) and predicted (190.45 pgEq/mL) Cm~ xvalues were simi- 
lar, as were the xperimental (2.00 hours) and calculated (2.58 hours) Tma x values. 
Distribution in Tissues 
Table II shows the tu2~. and the mean residence time (MRT) of the radioactivi- 
ty in selected tissues. Fifteen minutes after study drug administration, radioac- 
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Figure 1. Mean (SD) total radioactivity accumulated in plasma from 0 to 144 hours 
after single-dose administration of oral D-004 radiolabeled with (3H)-oleic 
acid in rats. 
Table I. Pharmacokinetic properties of radioactivity after single-dose 
administration of oral D-004 radiolabeled with (3H)-oleic acid 
to rats. Values are means except where otherwise marked. 
Property Value 
Experimental Cmax, mean (SD), MgEq/mL 195.56 (31.1 2) 
Predicted Cmax, IJgEq/mL 190.45 
Experimental Tmax, h 2.00 
Predicted Trnax , h 2.58 
tl/2~, h 1.33 
tl/21 > h 36.07 
Predicted AUC0_144 h, IJgEq/mL • h -1 5368.40 
ka, h 1.31 
ke, h 8.67 
r 2 0.99 
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Table II. Pharmacokinetic parameters of the distribution of radioactivity 
in tissues. Values are mean hours. 
Tissue tl/2~ M RT 
Prostate 181.93 260.23 
Adipose tissue 141.02 225.27 
Adrenal glands 92.24 134.36 
Testes 79.45 116.14 
Seminal vesicles 60.27 90.04 
Small intestine 45.92 65.10 
Liver 35.60 52.44 
MRT = mean residence time. 
tivity was broadly distributed in plasma and all the tissues examined. 
However, the time course varied in the different tissues, as shown by the 
AUC at the intervals of 0 to 8 hours, 0 to 24 hours, and 0 to 144 hours after 
study drug administration (Figure 2). Within the first 8 hours (Figure 2A), 
the highest TR values were detected in the prostate, followed by the liver, 
small intestine, and plasma. For the interval 0 to 24 hours (Figure 2B), the 
prostate, adipose tissue, liver, plasma, and small intestine still had the high- 
est TR values, but radioactivity had increased in the small intestine and 
decreased in the liver with respect o the first hours (Figure 2A). The peak 
radioactivity occurred later in the small intestine (at 4 hours) than in the 
liver (at 2 hours). In the small intestine and the liver, tl/2~ " values were 45.92 
and 35.60 hours, respectively, and MRT values were 65.10 and 52.44 hours, 
respectively (Table II). 
During the period of 0 to 144 hours after study drug administration, a large 
change occurred in the AUC of radioactivity of the adipose tissue (Figure 2C). 
While radioactivity decreased in the tissues and plasma, a gradual and sustained 
increase in radioactivity was found in adipose tissue. After 24 and 144 hours, 
AUC in the adipose tissue was second only to that in the prostate (Figures 2B 
and 2C). 
Figure 3 shows the distribution of total radioactivity in the prostate over 
time, with mean Cma x being 562.41 IJgEq/g and mean Tma x being 4 hours 
and decreasing slowly thereafter. The mean value measured at 8 hours 
(522.87 IJgEq/g) was similar to that found at 2 hours; the values remained ele- 
vated after 24 and 72 hours (498.43 and 416.41 iJgEq/g, respectively). From 0 to 
144 hours after study drug administration, the prostate had the longest mean 
tl/2~ " (181.93 hours) and the greatest MRT (260.23 hours) and cumulative 
AUC values compared with plasma and the other tissues studied (Table II). 
Thus, the AUC value was higher in the prostate compared with all of the other 
sites studied, including the testes and seminal vesicles (Figure 4). 
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Time After Study Drug Administration (h) 
Figure 3. Total radioactivity in the prostate 0 to 144 hours after oral administration 
of a dose of D-004 radiolabeled with (3H)-oleic acid in rats. 
Excret ion  o f  Rad ioact iv i ty  
Table III summarizes the urinary and fecal excretion of radioactivity. At 
144 hours after study drug administration, total mean (SD) excretion was 
62.40% (5.90%) of the administered ose-- feces (33.48% [4.90%]) and urine 
(28.96% [5.32%]). While almost half of the radioactivity recovered in the 
urine was excreted within the first 24 hours (13.30% [2.25%]), 13.90% (4.62%) 
and 24.08% (5.10%) of the administered oses were excreted in the feces 
after 24 and 48 hours, respectively. 
DISCUSSION 
After single-dose administration of oral D-004 radiolabeled with (~H)-oleic acid, 
absorption was rapid, as indicated by the high plasma radioactivity levels 
reached after 15 minutes and the Tma x (2 hours). The plasma concentration- 
time pattern fit an open, 2-compartment pharmacokinetic model, accounting 
for a rapid first distribution phase, in which plasma levels fell sharply, and a 
slower second elimination phase. The consistency between the experimental 
and predicted values of Cma x and Tma x suggests that the experimental values 
matched a 2-phase limination process. 
The tissue distribution of radioactivity was rapid and broad. Concentrations 
of radioactivity in tested tissues were high beginning with the first samples, 
which were obtained at 15 minutes after study drug administration. Tissue- 
specific distributions of radioactivity were observed, with a different time 
course for each source. Thus, for the first interval (0-8 hours), the prostate, 
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Figure 4. Ratio of the AUC of radioactivity in selected tissues and plasma. 
Table III. Cumulative excretion of radioactivity (feces and urine) after 
single-dose administration of oral (3H)-oleic acid in rats. 
Values are mean (SD) %. 
Collection Period, h Excretion 
Feces 
0-24 13.90 (4.62) 
0~,8 24.08 (5.1 O) 
0-72 25.97 (5.39) 
0-96 29.13 (4.49) 
0-120 30.53 (4.40) 
0-144 33.48 (4.90) 
Urine 
0-24 13.03 (2.25) 
0-48 16.76 (2.05) 
0-72 21.03 (2.01) 
0-96 23.68 (3.63) 
0-120 26.01 (4.37) 
0-144 28.96 (5.32) 
Total (feces + urine) 62.40 (5.90) 
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followed by the liver, small intestine, and plasma, was found to have the high- 
est TR value. The high TR values in the liver and small intestine suggest a first- 
pass effect in these organs. However, the clinical relevance of this finding is 
believed to be limited because the cumulative AUC values in liver, small intes- 
tine, and plasma were similar, allowing substantial systemic bioavailability of 
radioactivity after oral administration of the radiolabeled compound. This 
result is consistent with the fact that most (>70%) of the radioactivity adminis- 
tered as radiolabeled oleic acid t6 and other free fatty acids of similar chain 
length were recovered in plasma in the first hours after administration. 
The high level of radioactivity found in the small intestine was expected 
because oils are metabolized and absorbed in the small intestine. However, dur- 
ing the first interval (0--8 hours), more radioactivity accumulated in the liver than 
in the small intestine. This finding was unexpected because drugs must cross the 
intestinal mucosa before entering the portal circulation and passing through the 
liver. A possible xplanation for this apparent contradiction is related to the dis- 
tinct mechanisms underlying the uptake of free fatty acids in both organs. In the 
liver, free fatty acids can enter tissues by simple diffusion or by a carrier protein 
system, 24-28 which occurs mainly via the chylomicron-remnant receptor. 29 How- 
ever, the intestinal mucosa can internalize free fatty acids in vivo from the blood- 
stream, 3° thereby allowing greater accumulation of radioactivity. 
The time course of the retention of radioactivity in adipose tissue appears to 
be as expected. In contrast to the other tissues tudied, radioactivity in adipose 
tissue increased throughout the study, suggesting that some of the radioactivi- 
ty that was not excreted finally accumulated in adipose tissue. This finding is 
consistent with the fact that triglycerides, as well as chylomicrons (from intes- 
tinal absorption) and lipoproteins (from hepatic synthesis), are hydrolyzed by 
lipase to glycerol and free fatty acids, which are then absorbed by adipocytes. 
Overall, the broad retention of radioactivity hroughout the tissues was con- 
sistent with its slow decay over time and with findings that 25% to 40% of orally 
administered (~4C)-oleic, -palmitic, and -stearic acids accumulated in organs 
and tissues. 3°,31 
After single-dose administration of oral D-004 radiolabeled with (3H)-oleic 
acid, the preponderance of radioactivity accumulated in the rat prostate, sug- 
gesting a preferential accumulation of radiolabeled oleic acid and/or its 
metabolites in this organ. This result supports the data regarding accumulation 
of TR after an oral dose of saw palmetto LE radiolabeled with (14C)-oleic and 
(14C)-lauric acids. 16 In addition, since oral D-004 therapy prevented PH in rats 
given T, 19-22 our findings indicate that a main component of D-004 and/or its 
metabolites reached the prostate, a target organ for the preventive ffect of this 
extract in T-induced PH in the rat. Because TR in prostate decreased slowly 
throughout the study period, it seems likely that higher concentrations could 
be achieved after repeated osing. 
Recovery of radioactivity 144 hours after oral administration was incomplete 
(62.40%), indicating slow elimination of the radioactivity, which is consistent 
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with retention of radioactivity in the different organs. Excretion of radioactivity 
via the fecal and urinary routes was similar--33.48% in feces and 28.96% in urine. 
In the present study, absolute availability and absorption data were not 
determined because we did not measure plasma radioactivity or TR excretion 
immediately after administration. 
Pharmacokinetic studies of substances consisting of mixtures of compounds, 
as are normally found in plant extracts, are particularly difficult, especially 
when these compounds and/or metabolites are endogenous, as occurs with 
mixtures of free fatty acids. 
In this study, we found that the radiolabeled compound and/or metabolites 
were broadly distributed across organs, including the prostate, supporting a
pharmacokinetic rationale for the preventive ffects of D-004 on PH induced 
with T in rats. Further studies, however, are needed to explore the pharmacoki- 
netic characteristics of other free fatty acids abundant in D-004, such as lauric 
and myristic acids, which also inhibit prostate 5~-reductase activity, 23 to obtain a 
more representative picture of the pharmacokinetic behavior of this substance. 
CONCLUSIONS 
This study found that in rats, after single-dose administration of oral D-004 ra- 
diolabeled with (3H)-oleic acid, absorption of radioactivity was rapid and wide- 
ly distributed across organs and tissues, with the prostate showing the greatest 
retention of radioactivity throughout the study. Total excretion was limited 
(62.40% of the administered dose), consistent with slow elimination and high 
retention of radioactivity in the tissues. A similar amount of radioactivity was 
excreted via the fecal and urinary routes. These results support the use of 
D-004 in preventing PH induced with T in rats. 
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